SIGA Technologies Inc logo

SIGA - SIGA Technologies Inc News Story

$7.14 -0.0  -0.3%

Last Trade - 21/01/21

Sector
Healthcare
Size
Mid Cap
Market Cap £405.9m
Enterprise Value £348.3m
Revenue £67.0m
Position in Universe 3282nd / 6622

SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020

Thu 12th November, 2020 9:05pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201112:nGNXbpm8pK


NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA)
(NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the
health security market, today announced that Dr. Dennis Hruby, Chief
Scientific Officer, will participate in a panel discussion at the
Non-Conventional Threats (NCT) Asia Virtual Conference.

The panel discussion titled, “COVID-19: Insights on an Epidemic Outbreak”
will take place at 12:00 p.m. Malaysia Time on Friday, November 13, 2020 with
Dr. Hruby speaking as one member of the panel at the conference.

“With the COVID-19 pandemic continuing its devastating global impact,
preparedness for the possibility of future pandemics are of increasing
importance for governments worldwide. We look forward to providing information
about TPOXX in addressing a potential smallpox outbreak, which is far more
lethal than COVID-19,” said Dr. Hruby.

ABOUT SIGA TECHNOLOGIES, INC. and TPOXX(®)

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused
on the health security market. Health security comprises countermeasures for
biological, chemical, radiological and nuclear attacks (biodefense market),
vaccines and therapies for emerging infectious diseases, and health
preparedness. Our lead product is TPOXX(®), also known as tecovirimat and
ST-246®, an orally administered and IV formulation antiviral drug for the
treatment of human smallpox disease caused by variola virus. TPOXX(®) is a
novel small-molecule drug and the US maintains a stockpile of 1.7 million
courses in the Strategic National Stockpile under Project BioShield. The oral
formulation of TPOXX(®) was approved by the FDA for the treatment of smallpox
in 2018. The full label is here:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fce826ab-4d6a-4139-a2ee-a304a913a253.
In September 2018, SIGA signed a contract potentially worth more than $600
million with BARDA for additional procurement and development related to both
oral and intravenous formulations of TPOXX(®). For more information about
SIGA, please visit www.siga.com.

About Smallpox(1)

Smallpox is a contagious, disfiguring and often deadly disease that has
affected humans for thousands of years. Naturally occurring smallpox was
eradicated worldwide by 1980, the result of an unprecedented global
immunization campaign. Samples of smallpox virus have been kept for research
purposes. This has led to concerns that smallpox could someday be used as a
biological warfare agent. A vaccine can prevent smallpox, but the risk of the
current vaccine's side effects is too high to justify routine vaccination for
people at low risk of exposure to the smallpox virus.

FORWARD-LOOKING STATEMENTS

This press release contains certain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Such forward-looking statements are subject to various known and unknown risks
and uncertainties, and SIGA cautions you that any forward-looking
information provided by or on behalf of SIGA is not a guarantee of future
performance. More detailed information about SIGA and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth
in SIGA's filings with the Securities and Exchange Commission,
including SIGA's Annual Report on Form 10-K for the year ended December 31,
2019, and in other documents that SIGA has filed with the SEC. SIGA urges
investors and security holders to read those documents free of charge at
the SEC's web site at http://www.sec.gov. Interested parties may also
obtain those documents free of charge from SIGA. Forward-looking statements
are current only as of the date on which such statements were made, and except
for our ongoing obligations under the United States of America federal
securities laws, we undertake no obligation to update publicly any
forward-looking statements whether as a result of new information, future
events, or otherwise.

The information contained in this press release does not necessarily reflect
the position or the policy of the Government and no official endorsement
should be inferred.

Contacts:
Investors
David Carey 
212-867-1768
david.carey@finnpartners.com

Media
Stephanie Seiler
206-713-0124
stephanie.seiler@finnpartners.com

(______________________________________)

(1)
http://www.mayoclinic.org/diseases-conditions/smallpox/basics/definition/con-20022769

(https://www.globenewswire.com/NewsRoom/AttachmentNg/f6bb4557-ff79-4aa8-88ef-c41de9ffd198)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.